(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide - 2Deadly heat worldwide prompts $300 million for climate health research at COP30
- 3Manual for Tracking down the Mysterious Cascades in China
- 4Home Security Frameworks with Shrewd Elements
- 5Make your choice for the PS5 game that you love playing with companions!
- Which Startup's Innovation Could Reform Medical care?
- Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- Most loved Real time feature: Which Stage Do You Like
- Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- Glen Powell will host 'Saturday Night Live' with Olivia Dean as musical guest: What to know ahead of their debut
- Grasping the Qualifications Among Separation and Dissolution
- As world leaders enter climate talks, people in poverty have the most at stake
- The Manual for Electric Vehicles that will be hot dealers in 2023
- Manual for Instructive Application for Youngsters
